Stocktoria
Century Therapeutics, Inc. IPSC
Century Therapeutics, Inc. (IPSC) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $109.2M at a -8.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.449 |
| Retained earnings / assets | -3.54 |
| EBIT / assets | -0.077 |
| Equity / liabilities | 2.454 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
FAQ
Is IPSC financially healthy?
Century Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IPSC pay a dividend?
No, Century Therapeutics, Inc. does not currently pay a dividend.
How profitable is IPSC?
In FY2025, Century Therapeutics, Inc. had a net margin of -8.8% and a return on equity of -6.0%.
What is the analyst price target for IPSC?
The average Wall-Street price target for Century Therapeutics, Inc. is $4.75, about 142.3% above the recent price, from 4 analysts.
Is IPSC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Century Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.